Investigational New Drugs

, Volume 29, Issue 5, pp 1090–1093 | Cite as

Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib

  • Romain Coriat
  • Stanislas Ropert
  • Olivier Mir
  • Bertrand Billemont
  • Stanislas Chaussade
  • Pierre-Philippe Massault
  • Benoit Blanchet
  • Olivier Vignaux
  • François Goldwasser
SHORT REPORT

Summary

Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents.

Keywords

Vascular Endothelial Growth Factor Bevacizumab Sorafenib Celiac Disease Sunitinib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Acknowledgments of research support for the study: none.

Competing interest

None.

References

  1. 1.
    Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109PubMedCrossRefGoogle Scholar
  2. 2.
    Atkins M, Jones CA, Kirkpatrick P (2006) Sunitinib maleate. Nat Rev 5:279–280CrossRefGoogle Scholar
  3. 3.
    Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA (2008) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95–96PubMedCrossRefGoogle Scholar
  4. 4.
    Heng Y, Schuffler MD, Haggitt RC, Rohrmann CA (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747–1758PubMedGoogle Scholar
  5. 5.
    Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35PubMedCrossRefGoogle Scholar
  6. 6.
    Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965–972PubMedCrossRefGoogle Scholar
  7. 7.
    Steeghs N, Rabelink TJ, Op’t Roodt J, et al (2009) Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann OncolGoogle Scholar
  8. 8.
    Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860–1869PubMedCrossRefGoogle Scholar
  9. 9.
    Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64:1295–1298PubMedCrossRefGoogle Scholar
  10. 10.
    Greenstein AJ, Nguyen SQ, Berlin A et al (2007) Pneumatosis intestinalis in adults: management, surgical indications, and risk factors for mortality. J Gastrointest Surg 11:1268–1274PubMedCrossRefGoogle Scholar
  11. 11.
    St Peter SD, Abbas MA, Kelly KA (2003) The spectrum of pneumatosis intestinalis. Arch Surg 138:68–75PubMedCrossRefGoogle Scholar
  12. 12.
    Ho LM, Paulson EK, Thompson WM (2007) Pneumatosis intestinalis in the adult: benign to life-threatening causes. Ajr 188:1604–1613PubMedCrossRefGoogle Scholar
  13. 13.
    Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989PubMedCrossRefGoogle Scholar
  14. 14.
    Mir O, Mouthon L, Alexandre J et al (2007) Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 99:85–86PubMedCrossRefGoogle Scholar
  15. 15.
    Loriot Y, Perlemuter G, Malka D et al (2008) Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clinical Practice 5:268–278Google Scholar
  16. 16.
    Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–568PubMedCrossRefGoogle Scholar
  17. 17.
    Flaig TW, Kim FJ, La Rosa FG et al (2009) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 27:83–87PubMedCrossRefGoogle Scholar
  18. 18.
    Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610–2621PubMedCrossRefGoogle Scholar
  19. 19.
    Cacheux W, Boisserie T, Staudacher L et al (2008) Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19:1659–1661PubMedCrossRefGoogle Scholar
  20. 20.
    Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Romain Coriat
    • 1
    • 2
    • 3
    • 7
  • Stanislas Ropert
    • 1
    • 2
  • Olivier Mir
    • 1
    • 2
  • Bertrand Billemont
    • 1
    • 2
  • Stanislas Chaussade
    • 1
    • 3
  • Pierre-Philippe Massault
    • 1
    • 4
  • Benoit Blanchet
    • 1
    • 5
  • Olivier Vignaux
    • 1
    • 6
  • François Goldwasser
    • 1
    • 2
  1. 1.Center for Research on Angiogenesis Inhibitors (CERIA)Université Paris Descartes, AP-HP, Teaching Hospital CochinParisFrance
  2. 2.Department of Medical OncologyTeaching Hospital CochinParisFrance
  3. 3.Department of GastroenterologyTeaching Hospital CochinParisFrance
  4. 4.Department of SurgeryTeaching Hospital CochinParisFrance
  5. 5.Laboratory of PharmacologyTeaching Hospital CochinParisFrance
  6. 6.Department of RadiologyTeaching Hospital CochinParisFrance
  7. 7.Center for Research on Angiogenesis Inhibitors (CERIA), Medical Oncology UnitUniversité Paris DescartesParisFrance

Personalised recommendations